Skip to Main Content
Children's Health | Headaches, Phase III

A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1)

What is the purpose of this trial?

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.

  • Trial with
    Eli Lilly and Company
  • Ages
    6 years - 17 years
  • Gender
    Both

Contact Information

For more information about this study, including how to volunteer, contact Erin Weidman

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

  • Last Updated
    03/06/2024
  • Study HIC
    #2000028680